IDENTIFICATION OF HIPPOCAMPUS-RELATED HUB GENES AND PATHWAYS IN ALZHEIMER’S DISEASE USING DIFFERENTIAL GENE EXPRESSION AND NETWORK ANALYSIS

Main Article Content

Muhammad Afzal
Muhammad Farrukh Tahir
Anam Khalid
Abdullah Sethar
Muhammad Ali
Muhammad Abbas
Sanobar Gull
Hidayatullah Soomro
Tamseel Saleem
Aatif Masood Ahmad Khan

Keywords

Alzheimer's Disease, GSE48350 dataset, Hub genes

Abstract

Alzheimer's Disease (AD) is a complex neurodegenerative disorder characterized by cognitive decline and memory loss, with the hippocampus being significantly affected. This study aimed to identify differentially expressed genes (DEGs) in the hippocampus of AD patients using the GSE48350 dataset. Through rigorous preprocessing and quality control, we identified 250 top DEGs, including 189 upregulated and 61 downregulated genes. Protein-protein interaction (PPI) network analysis revealed SRC, BTK, and CD80 as key hub genes, indicating their central roles in AD pathology. Functional enrichment analysis of these hub genes highlighted several significantly overrepresented pathways, including Thiamine metabolism, Regulation of lipolysis in adipocytes, Axon guidance, Influenza A, Calcium signaling, and Thermogenesis. These findings underscore the critical involvement of synaptic function, neuroinflammation, and immune modulation in AD and suggest potential metabolic and neurodevelopmental links to the disease. This study provides new insights into the molecular mechanisms of AD and identifies potential therapeutic targets for future research.

Abstract 167 | Pdf Downloads 33

References

[1] Birajdar SV, Mulchandani M, Mazahir F and Yadav AK. Dementia and neurodegenerative disorder: An introduction. In: editors. Nanomedicine-based approaches for the treatment of dementia. Elsevier; 2023. p. 1-36.
[2] Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, Cummings J and van der Flier WM. Alzheimer's disease. The Lancet 2021; 397: 1577-1590.
[3] Penke B, Szűcs M and Bogár F. New pathways identify novel drug targets for the prevention and treatment of Alzheimer’s disease. International journal of molecular sciences 2023; 24: 5383.
[4] Revi M. Alzheimer’s disease therapeutic approaches. GeNeDis 2018: Genetics and Neurodegeneration 2020; 105-116.
[5] Islam Bu, Jabir NR and Tabrez S. The role of mitochondrial defects and oxidative stress in Alzheimer’s disease. Journal of Drug Targeting 2019; 27: 932-942.
[6] Sosa-Ortiz AL, Acosta-Castillo I and Prince MJ. Epidemiology of dementias and Alzheimer’s disease. Archives of medical research 2012; 43: 600-608.
[7] Mufson EJ, Mahady L, Waters D, Counts SE, Perez SE, DeKosky S, Ginsberg SD, Ikonomovic MD, Scheff S and Binder L. Hippocampal plasticity during the progression of Alzheimer’s disease. Neuroscience 2015; 309: 51-67.
[8] Mu Y and Gage FH. Adult hippocampal neurogenesis and its role in Alzheimer's disease. Molecular neurodegeneration 2011; 6: 1-9.
[9] Duyckaerts C and Dickson D. Neuropathology of Alzheimer's disease and its variants. Neurodegeneration: the molecular pathology of dementia and movement disorders 2011; 62-91.
[10] Morrison JH and Hof PR. Selective vulnerability of corticocortical and hippocampal circuits in aging and Alzheimer's disease. Progress in brain research 2002; 136: 467-486.
[11] Braak H and Del Tredici K. Neuroanatomy and pathology of sporadic Alzheimer's disease. 2014;
[12] Barrett T, Suzek TO, Troup DB, Wilhite SE, Ngau W-C, Ledoux P, Rudnev D, Lash AE, Fujibuchi W and Edgar R. NCBI GEO: mining millions of expression profiles—database and tools. Nucleic acids research 2005; 33: D562-D566.
[13] de Pins B, Mendes T, Giralt A and Girault J-A. The non-receptor tyrosine kinase Pyk2 in brain function and neurological and psychiatric diseases. Frontiers in Synaptic Neuroscience 2021; 13: 749001.
[14] McDonald C, Xanthopoulos C and Kostareli E. The role of Bruton's tyrosine kinase in the immune system and disease. Immunology 2021; 164: 722-736.
[15] Mir MA and Agrewala JN. Influence of CD80 and CD86 co-stimulation in the modulation of the activation of antigen presenting cells. Current Immunology Reviews 2007; 3: 160-169.
[16] Buchake V, Muthal A, Saudagar R and Bachhav R. A neurodegenerative disorder-Alzheimer disease: A treatise. Research Journal of Pharmacology and Pharmacodynamics 2010; 2: 268-273.
[17] Trojsi F, Christidi F, Migliaccio R, Santamaría-García H and Santangelo G. Behavioural and cognitive changes in neurodegenerative diseases and brain injury. Behavioural neurology 2018; 2018:
[18] Cummings JL. Cognitive and behavioral heterogeneity in Alzheimer’s disease: seeking the neurobiological basis. Neurobiology of aging 2000; 21: 845-861.
[19] Marcello E, Epis R, Saraceno C and Di Luca M. Synaptic dysfunction in Alzheimer’s disease. Synaptic Plasticity: Dynamics, Development and Disease 2012; 573-601.
[20] Albertini C. Development of new chemical entities to target neuroinflammatory pathways. 2022;
[21] Grosche L, Knippertz I, König C, Royzman D, Wild AB, Zinser E, Sticht H, Muller YA, Steinkasserer A and Lechmann M. The CD83 molecule–an important immune checkpoint. Frontiers in Immunology 2020; 11: 721.

Most read articles by the same author(s)

<< < 1 2 3